We serve Chemical Name:6-methyl-2-pyrrolidin-2-yl-1H-benzimidazole CAS:885278-00-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-methyl-2-pyrrolidin-2-yl-1H-benzimidazole
CAS.NO:885278-00-2
Synonyms:6-methyl-2-pyrrolidin-2-yl-1h-benzoimidazole
Molecular Formula:C12H15N3
Molecular Weight:201.26800
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:443.9ºC at 760 mmHg
Density:1.177g/cm3
Index of Refraction:1.638
PSA:40.71000
Exact Mass:201.12700
LogP:2.62460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-methyl-2-pyrrolidin-2-yl-1h-benzoimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-methyl-2-pyrrolidin-2-yl-1h-benzoimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-methyl-2-pyrrolidin-2-yl-1h-benzoimidazole Use and application,6-methyl-2-pyrrolidin-2-yl-1h-benzoimidazole technical grade,usp/ep/jp grade.
Related News: Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 1H-Indole-3-carboxamide,N-[4-[(dimethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- manufacturers One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. rel-methyl (1R,2S,3R,5S)-3-(4-bromophenyl)-8-oxabicyclo[3.2.1]octane-2-carboxylate suppliers “His strong track record of success and deep experience of fast-moving consumer goods and consumer health, proven at P&G, Novartis and GSK, means he is the right choice” to lead the consumer health unit as an independent company, GSK Chairman Jonanthan Symonds said of McNamara in the statement. 6-N-acetyl-5′-O-tert-butyldimethylsilyl-8-oxoadenosine vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 1H-Indole-3-carboxamide,N-[4-[(dimethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- manufacturers One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. rel-methyl (1R,2S,3R,5S)-3-(4-bromophenyl)-8-oxabicyclo[3.2.1]octane-2-carboxylate suppliers “His strong track record of success and deep experience of fast-moving consumer goods and consumer health, proven at P&G, Novartis and GSK, means he is the right choice” to lead the consumer health unit as an independent company, GSK Chairman Jonanthan Symonds said of McNamara in the statement. 6-N-acetyl-5′-O-tert-butyldimethylsilyl-8-oxoadenosine vendor & factory.
